A clinical trial assessing PTD802
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs PTD 802 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- 24 Jan 2025 New trial record
- 14 Jan 2025 According to Pheno Therapeutics media release, has received clinical trial authorisation (CTA) from the UKs MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.